| Mode of drug delivery |
Title (number) |
Rationale for chronotherapy and
features of patented systems |
| Oral tablet based |
IR gastrointestinal drug delivery system
(US6531152) |
Diseases of alimentary tract, system able to release drug at specific locations within GIT [38,39]. |
| Oral tablet based |
Pulsatile particles drug delivery system
(US5260069) |
Hypertension, unit dosage form for delivering drugs into the body in a series of sequential, pulsatile fashion. The system can be used with drugs that cannot be released by diffusion through a porous coating such as Water-insoluble drugs [40]. |
| Oral tablet based |
Pharmaceutical compositions (US4897270) |
Infection of gram-positive and gram-negative microorganisms, conventional film-coated tablets reduce the bioavailability of cefuroxime axetil and the invention overcomes this by control of the film coat rupture time and use of a tablet core, which disintegrates immediately following rupture of the film coat [41]. |
| Oral tablet based |
Pharmaceutical tablet suitable to deliver the active substance in subsequent and pre-determinable times (US6294200) |
Gastroesophageal reflux disease, Pharmaceutical tablet dosage form, capable of delivering the active substance with three pulses to a pre-determinable release profile [42]. |
| Oral tablet based |
Delayed total release two pulse gastrointestinal drug delivery system (US6632451) |
Analgesic and anti-inflammatory, a two pulse delivery device for delivering one or more active agents at colon [43]. |
| Oral tablet based |
Press coated pulsatile drug delivery system
suitable for oral administration (US6372254) |
Anti-inflammatory, a press coated pulsatile drug delivery system with an immediate release and an extended release compartment with TPR [44]. |
| Oral tablet based |
Multi-unit delivery system (US5110597) |
Helminth infections, system provides pulsed delivery of a single drug or different drugs or drug formulations suited to the delivery of pharmacologically. Especially suited for active peptides and protein anabolic hormones [45]. |
| Oral tablet based |
Controlled release flutamide composition (US5162117) |
Prostate cancer, invention provides controlled release form which is designed to provide an IR dose and a second pulsed delayed release dose [46]. |
Capsule based
(delivery device
with orifice) |
Delivery devices with pulsatile effect
(EP0627231) |
Invention lies in the field of pulsatile delivery of drugs, nutrients. The pulsatile effect achieved by parameters as choice of elastic material for the band, the thickness of the band made from the elastic material, the configuration and location of the orifice, and the viscosity and surface tension of the active agent formulation [47]. |
| Transdermal device |
Pulsating transdermal drug delivery system
(US5013293)
Pulsating transdermal drug delivery system
(US5312325) |
Diabetes mellitus and cancer provide an electrophoretic/electro-osmotic transdermal drug delivery system that rhythmically delivers a therapeutic compound in response to application of current pulsations to the system [48,49]. |
| Hydrogel system |
Pulsatile drug delivery device using stimuli
sensitive hydrogel (US 5226902) |
Diabetes mellitus, invention relates to delivery of drug laden hydrogels which Deswell and gives pulsatile release of drugs in response to external or internal stimuli such as temperature or pH changes, or chemical reactions [50]. |
